Navigation Links
Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression

rrence.

Yan Deschaintre, MD, FRCP(C), of the Centre Memoire, Hopital Roger Salengro, Lille, France and colleagues investigated whether vascular risk factors treatment slows cognitive decline once Alzheimer's and/or vascular dementia is already evident.

The researchers analysed medical records of patients attending their memory clinic for the first time between 1997 and 2003 inclusively who had a final diagnosis of Alzhiemer's, Alzhiemer's with cerebro-vascular disease, or vascular dementia. Vascular risk factors sought were high blood pressure, diabetes, dyslipidemia, and atherosclerotic vascular disease. The patients were considered treated if they received an antihypertensive, an oral antihyperglycemic or insulin, a statin or a fibrate, an antiplatelet, or an anticoagulant.

Among the 891 dementia patients studied, the researchers found that those who had their vascular risk factors treated declined less than those who had not. For people with Alzheimer's without signs of vascular dementia, vascular risk factors treatment reduced yearly cognitive decline by almost one third, according to the mini-mental state evaluation (MMSE) score.

"That means the patients whose vascular risk factors were treated declined at a slower rate such that it took them three years to decline as much as untreated patients did after two years," Deschaintre said.

"Most of the social and financial burden caused by Alzheimer's and dementia is generated by the later, more severe stages of the disease," Deschaintre said. "By slowing dementia progression, vascular risk factors treatment may delay the severe stages and have a significant impact on reducing the burden of dementia."

Atherosclerosis Surgery and Stroke or TIA Associated with Increased Risk of MCI

Carotid endarterectomy is performed when a major blood vessel that supplies blood to the brain is blocked as a result of atherosclerosis. Atherosclerosis in blood vessels in the brain reduces
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
4. Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohns Disease
5. Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases
6. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
7. New Data Shows Once a Day Lamictal XR is Effective in Treating Patients with Partial Seizures
8. Targeting Specific Mutations Reveals Promising New Approach to Treating Genetic Disorders; Preclinical Data Published in Nature
9. Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting
10. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
11. Stanford Study Finds No Conclusive Benefit From Treating Kleptomania With Medication
Post Your Comments:
Breaking Medicine News(10 mins):Health News:Blood Thinner Combos Risky for Heart Attack Patients 2Health News:Centegra Expands H1N1 Vaccines to General Public 2Health News:Centegra Expands H1N1 Vaccines to General Public 3Health News:Centegra Expands H1N1 Vaccines to General Public 4Health News:Do Charitable Gift Donations Make a Difference? 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 4Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 5Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 6Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 7Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 8Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 9Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 10Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 11Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 12Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 13Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 14Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 15Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 16Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 2Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 3Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 4Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 5Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 6